Cannabinoid 1 receptors are critical for the innate immune response to TLR4 stimulation

American Journal of Physiology - Regulatory Integrative and Comparative Physiology

Volumn 305, Issue 3, 2013, Pages

  Duncan, Marnie ^a   Galic, Michael A ^a   Wang, Arthur ^a   Chambers, Adam P ^a   McCafferty, Donna Marie ^a   McKay, Derek M ^a   Sharkey, Keith A ^a   Pittman, Quentin J ^a  

^a UNIVERSITY OF CALGARY   (Canada)

Author keywords

Cytokine; Endocannabinoid; Fever; Toll like receptor

Indexed keywords

CANNABINOID 1 RECEPTOR; LIPOPOLYSACCHARIDE; MESSENGER RNA; POLYINOSINIC POLYCYTIDYLIC ACID; PROTEIN C FOS; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEVER; INNATE IMMUNITY; LIVER; MALE; MOUSE; NONHUMAN; PERITONEUM MACROPHAGE; PRIORITY JOURNAL; SPLEEN; THERMOGENESIS;

CYTOKINE; ENDOCANNABINOID; FEVER; TOLL-LIKE RECEPTOR;

ANIMALS; BODY TEMPERATURE; CYTOKINES; DATA INTERPRETATION, STATISTICAL; FEVER; HYPERALGESIA; IMMUNITY, INNATE; LIPOPOLYSACCHARIDES; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PAIN MEASUREMENT; PIPERIDINES; POLY I-C; PROTO-ONCOGENE PROTEINS C-FOS; PYRAZOLES; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTOR, CANNABINOID, CB1; RNA; TOLL-LIKE RECEPTOR 3; TOLL-LIKE RECEPTOR 4;

EID: 84880993814     PISSN: 03636119     EISSN: 15221490     Source Type: Journal    
DOI: 10.1152/ajpregu.00104.2013     Document Type: Article

References (64)

1. Agarwal N, Pacher P, Tegeder I, Amaya F, Constantin CE, Brenner GJ, Rubino T, Michalski CW, Marsicano G, Monory K, Mackie K, Marian C, Batkai S, Parolaro D, Fischer MJ, Reeh P, Kunos G, Kress M, Lutz B, Woolf CJ, Kuner R. Cannabinoids mediate analgesia largely via peripheral type 1 cannabinoid receptors in nociceptors. Nat Neurosci 10: 870-879, 2007.
2. Akira S, Takeda K, Kaisho T. Toll-like receptors: critical proteins linking innate and acquired immunity. Nat Immunol 2: 675-680, 2001.
3. Anand P, Whiteside G, Fowler CJ, Hohmann AG. Targeting CB2 receptors and the endocannabinoid system for the treatment of pain. Brain Res Rev 60: 255-266, 2009.
4. Atwood BK, Mackie K. CB2: a cannabinoid receptor with an identity crisis. Br J Pharmacol 160: 467-479, 2010.
5. Benamar K, Yondorf M, Meissler JJ, Geller EB, Tallarida RJ, Eisenstein TK, Adler MW. A novel role of cannabinoids: implication in the fever induced by bacterial lipopolysaccharide. J Pharmacol Exp Ther 320: 1127-1133, 2007.
6. Berdyshev EV. Cannabinoid receptors and the regulation of immune response. Chem Phys Lipids 108: 169-190, 2000.
7. Blatteis CM. The onset of fever: new insights into its mechanism. Prog Brain Res 162: 3-14, 2007.
8. Burston JJ, Sim-Selley LJ, Harloe JP, Mahadevan A, Razdan RK, Selley DE, Wiley JL. N-arachidonyl maleimide potentiates the pharmacological and biochemical effects of the endocannabinoid 2-arachidonylglycerol through inhibition of monoacylglycerol lipase. J Pharmacol Exp Ther 327: 546-553, 2008.
9. Castillo PE, Younts TJ, Chavez AE, Hashimotodani Y. Endocannabinoid signaling and synaptic function. Neuron 76: 70-81, 2012.
10. Chaperon F, Thiebot MH. Behavioral effects of cannabinoid agents in animals. Crit Rev Neurobiol 13: 243-281, 1999.
11. Conti B, Tabarean I, Andrei C, Bartfai T. Cytokines and fever. Front Biosci 9: 1433-1449, 2004.
12. Crawley JN, Corwin RL, Robinson JK, Felder CC, Devane WA, Axelrod J. Anandamide, an endogenous ligand of the cannabinoid receptor, induces hypomotility and hypothermia in vivo in rodents. Pharmacol Biochem Behav 46: 967-972, 1993.
13. Cunningham C, Campion S, Teeling J, Felton L, Perry VH. The sickness behaviour and CNS inflammatory mediator profile induced by systemic challenge of mice with synthetic double-stranded RNA (poly I:C). Brain Behav Immun 21: 490-502, 2007.
14. Dantzer R, Kelley KW. Twenty years of research on cytokine-induced sickness behavior. Brain Behav Immun 21: 153-160, 2007.
15. Ellis S, Mouihate A, Pittman QJ. Neonatal programming of the rat neuroimmune response: stimulus specific changes elicited by bacterial and viral mimetics. J Physiol 571: 695-701, 2006.
16. Fennessy MR, Taylor DA. The effect of delta9-tetrahydrocannabinol on body temperature and brain amine concentrations in the rat at different ambient temperatures. Br J Pharmacol 60: 65-71, 1977.
17. Fioravanti B, De Felice M, Stucky CL, Medler KA, Luo MC, Gardell LR, Ibrahim M, Malan TP Jr, Yamamura HI, Ossipov MH, King T, Lai J, Porreca F, Vanderah TW. Constitutive activity at the cannabinoid CB1 receptor is required for behavioral response to noxious chemical stimulation of TRPV1: antinociceptive actions of CB1 inverse agonists. J Neurosci 28: 11593-11602, 2008.
18. Fitton AG, Pertwee RG. Changes in body temperature and oxygen consumption rate of conscious mice produced by intrahypothalamic and intracerebroventricular injections of delta 9-tetrahydrocannabinol. Br J Pharmacol 75: 409-414, 1982.
19. Fortier ME, Kent S, Ashdown H, Poole S, Boksa P, Luheshi GN. The viral mimic, polyinosinic:polycytidylic acid, induces fever in rats via an interleukin-1-dependent mechanism. Am J Physiol Regul Integr Comp Physiol 287: R759-R766, 2004.
20. Fraga D, Zanoni CI, Rae GA, Parada CA, Souza GE. Endogenous cannabinoids induce fever through the activation of CB1 receptors. Br J Pharmacol 157: 1494-1501, 2009.
21. Frankel N. Multiple layers of complexity in cis-regulatory regions of developmental genes. Dev Dyn 241: 1857-1866, 2012.
22. Galic MA, Persinger MA. Lagged association between geomagnetic activity and diminished nocturnal pain thresholds in mice. Bioelectromagnetics 28: 577-579, 2007.
23. Harkany T, Guzman M, Galve-Roperh I, Berghuis P, Devi LA, Mackie K. The emerging functions of endocannabinoid signaling during CNS development. Trends Pharmacol Sci 28: 83-92, 2007.
24. Hart BL. Biological basis of the behavior of sick animals. Neurosci Biobehav Rev 12: 123-137, 1988.
25. Hill MN, Hillard CJ, Bambico FR, Patel S, Gorzalka BB, Gobbi G. The therapeutic potential of the endocannabinoid system for the development of a novel class of antidepressants. Trends Pharmacol Sci 30: 484-493, 2009.
26. Hons IM, Storr MA, Mackie K, Lutz B, Pittman QJ, Mawe GM, Sharkey KA. Plasticity of mouse enteric synapses mediated through endocannabinoid and purinergic signaling. Neurogastroenterol Motil 24: e113-e124, 2012.
27. Hu H, Ho W, Mackie K, Pittman QJ, Sharkey KA. Brain CB(1) receptor expression following lipopolysaccharide-induced inflammation. Neuroscience 227: 211-222, 2012.
28. Kalis C, Kanzler B, Lembo A, Poltorak A, Galanos C, Freudenberg MA. Toll-like receptor 4 expression levels determine the degree of LPS-susceptibility in mice. Eur J Immunol 33: 798-805, 2003.
29. Kano M, Ohno-Shosaku T, Hashimotodani Y, Uchigashima M, Watanabe M. Endocannabinoid-mediated control of synaptic transmission. Physiol Rev 89: 309-380, 2009.
30. Kluger MJ, Kozak W, Conn CA, Leon LR, Soszynski D. Role of fever in disease. Ann NY Acad Sci 856: 224-233, 1998.
31. Lane DA, Chan J, Lupica CR, Pickel VM. Cannabinoid-1 receptor gene deletion has a compartment-specific affect on the dendritic and axonal availability of mu-opioid receptors and on dopamine axons in the mouse nucleus accumbens. Synapse 64: 886-897, 2010.
32. Leon CG, Tory R, Jia J, Sivak O, Wasan KM. Discovery and development of toll-like receptor 4 (TLR4) antagonists: a new paradigm for treating sepsis and other diseases. Pharm Res 25: 1751-1761, 2008.
33. Maier SF, Wiertelak EP, Martin D, Watkins LR. Interleukin-1 mediates the behavioral hyperalgesia produced by lithium chloride and endotoxin. Brain Res 623: 321-324, 1993.
34. Marsicano G, Lutz B. Expression of the cannabinoid receptor CB1 in distinct neuronal subpopulations in the adult mouse forebrain. Eur J Neurosci 11: 4213-4225, 1999.
35. Marsicano G, Wotjak CT, Azad SC, Bisogno T, Rammes G, Cascio MG, Hermann H, Tang J, Hofmann C, Zieglgansberger W, Di M, V, Lutz B. The endogenous cannabinoid system controls extinction of aversive memories. Nature 418: 530-534, 2002.
36. Massi P, Vaccani A, Parolaro D. Cannabinoids, immune system and cytokine network. Curr Pharm Des 12: 3135-3146, 2006.
37. Matsumoto M, Seya T. TLR3: interferon induction by double-stranded RNA including poly(I:C). Adv Drug Deliv Rev 60: 805-812, 2008.
38. Mouihate A, Galic MA, Ellis SL, Spencer SJ, Tsutsui S, Pittman QJ. Early life activation of Toll-like receptor 4 reprograms neural antiinflammatory pathways. J Neurosci 30: 7975-7983, 2010.
39. Nomura F, Akashi S, Sakao Y, Sato S, Kawai T, Matsumoto M, Nakanishi K, Kimoto M, Miyake K, Takeda K, Akira S. Cutting edge: endotoxin tolerance in mouse peritoneal macrophages correlates with down-regulation of surface Toll-like receptor 4 expression. J Immunol 164: 3476-3479, 2000.
40. Ovadia H, Wohlman A, Mechoulam R, Weidenfeld J. Characterization of the hypothermic effect of the synthetic cannabinoid HU-210 in the rat. Relation to the adrenergic system and endogenous pyrogens. Neuropharmacology 34: 175-180, 1995.
41. Paldy E, Borcel E, Higuera-Matas A, Lopez-Montoya G, Wenger T, Toth G, Borsodi A, Ambrosio E. CNR1 gene deletion affects the density of endomorphin-2 binding sites in the mouse brain in a hemispherespecific manner. Eur J Pharmacol 698: 220-227, 2013.
42. Parolaro D. Presence and functional regulation of cannabinoid receptors in immune cells. Life Sci 65: 637-644, 1999.
43. Pertwee RG, Ross RA. Cannabinoid receptors and their ligands. Prostaglandins Leukot Essent Fatty Acids 66: 101-121, 2002.
44. Rawls SM, Cabassa J, Geller EB, Adler MW. CB1 receptors in the preoptic anterior hypothalamus regulate WIN 55212-2 [(4,5-dihydro-2-methyl-4(4-morpholinylmethyl)-1-(1-naphthalenyl-carbonyl)-6H-pyrr olo[3,2,1ij]quinolin-6-one]-induced hypothermia. J Pharmacol Exp Ther 301: 963-968, 2002.
45. Roche M, Diamond M, Kelly JP, Finn DP. In vivo modulation of LPS-induced alterations in brain and peripheral cytokines and HPA axis activity by cannabinoids. J Neuroimmunol 181: 57-67, 2006.
46. Romanovsky AA. Thermoregulation: some concepts have changed. Functional architecture of the thermoregulatory system. Am J Physiol Regul Integr Comp Physiol 292: R37-R46, 2007.
47. Romanovsky AA, Almeida MC, Aronoff DM, Ivanov AI, Konsman JP, Steiner AA, Turek VF. Fever and hypothermia in systemic inflammation: recent discoveries and revisions. Front Biosci 10: 2193-2216, 2005.
48. Romanovsky AA, Kulchitsky VA, Akulich NV, Koulchitsky SV, Simons CT, Sessler DI, Gourine VN. First and second phases of biphasic fever: two sequential stages of the sickness syndrome? Am J Physiol Regul Integr Comp Physiol 271: R244-R253, 1996.
49. Rudaya AY, Steiner AA, Robbins JR, Dragic AS, Romanovsky AA. Thermoregulatory responses to lipopolysaccharide in the mouse: dependence on the dose and ambient temperature. Am J Physiol Regul Integr Comp Physiol 289: R1244-R1252, 2005.
50. Schulte K, Steingruber N, Jergas B, Redmer A, Kurz CM, Buchalla R, Lutz B, Zimmer A, Schlicker E. Cannabinoid CB1 receptor activation, pharmacological blockade, or genetic ablation affects the function of the muscarinic auto- and heteroreceptor. Naunyn Schmiedebergs Arch Pharmacol 385: 385-396, 2012.
51. Shavit Y, Cohen E, Gagin R, Avitsur R, Pollak Y, Chaikin G, Wolf G, Yirmiya R. Effects of prenatal morphine exposure on NK cytotoxicity and responsiveness to LPS in rats. Pharmacol Biochem Behav 59: 835-841, 1998.
52. Sofia RD. A paradoxical effect for 1-tetrahydrocannabinol on rectal temperature in rats. Res Commun Chem Pathol Pharmacol 4: 281-288, 1972.
53. Steiner AA, Chakravarty S, Rudaya AY, Herkenham M, Romanovsky AA. Bacterial lipopolysaccharide fever is initiated via Toll-like receptor 4 on hematopoietic cells. Blood 107: 4000-4002, 2006.
54. Steiner AA, Molchanova AY, Dogan MD, Patel S, Petervari E, Balasko M, Wanner SP, Eales J, Oliveira DL, Gavva NR, Almeida MC, Szekely M, Romanovsky AA. The hypothermic response to bacterial lipopolysaccharide critically depends on brain CB1, but not CB2 or TRPV1, receptors. J Physiol 589: 2415-2431, 2011.
55. Stella N. Cannabinoid and cannabinoid-like receptors in microglia, astrocytes, and astrocytomas. Glia 58: 1017-1030, 2010.
56. Van Sickle MD, Duncan M, Kingsley PJ, Mouihate A, Urbani P, Mackie K, Stella N, Makriyannis A, Piomelli D, Davison JS, Marnett LJ, Di M, V, Pittman QJ, Patel KD, Sharkey KA. Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science 310: 329-332, 2005.
57. Varga K, Wagner JA, Bridgen DT, Kunos G. Platelet- and macrophagederived endogenous cannabinoids are involved in endotoxin-induced hypotension. FASEB J 12: 1035-1044, 1998.
58. Voss T, Barth SW, Rummel C, Gerstberger R, Hubschle T, Roth J. STAT3 and COX-2 activation in the guinea-pig brain during fever induced by the Toll-like receptor-3 agonist polyinosinic:polycytidylic acid. Cell Tissue Res 328: 549-561, 2007.
59. Wang J, Ueda N. Biology of endocannabinoid synthesis system. Prostaglandins Other Lipid Mediat 89: 112-119, 2009.
60. Watkins LR, Goehler LE, Relton J, Brewer MT, Maier SF. Mechanisms of tumor necrosis factor-alpha (TNF-) hyperalgesia. Brain Res 692: 244-250, 1995.
61. Watkins LR, Wiertelak EP, Goehler LE, Smith KP, Martin D, Maier SF. Characterization of cytokine-induced hyperalgesia. Brain Res 654: 15-26, 1994.
62. Wiertelak EP, Smith KP, Furness L, Mooney-Heiberger K, Mayr T, Maier SF, Watkins LR. Acute and conditioned hyperalgesic responses to illness. Pain 56: 227-234, 1994.
63. Yirmiya R, Rosen H, Donchin O, Ovadia H. Behavioral effects of lipopolysaccharide in rats: involvement of endogenous opioids. Brain Res 648: 80-86, 1994.
64. Zimmer A, Zimmer AM, Hohmann AG, Herkenham M, Bonner TI. Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice. Proc Natl Acad Sci USA 96: 5780-5785, 1999.